| GBA1 — Glucocerebrosidase | |
|---|---|
| Symbol | GBA1 |
| Full Name | Glucosylceramidase Beta 1 |
| Chromosome | 1q22 |
| NCBI Gene | 2629 |
| Ensembl | ENSG00000177693 |
| OMIM | 606463 |
| UniProt | P04062 |
| Enzyme | Hydrolase (lysosomal) |
| Diseases | Parkinson's, DLB, Gaucher Disease |
| Brain Expression | Substantia nigra, Cortex, Hippocampus, Microglia |
| Key Mutations | |
| N370S, L444P, 84GG, IVS2+1 | |
Expanded Gba1 Page is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GBA1 encodes glucocerebrosidase (GCase), a lysosomal hydrolase that catalyzes the breakdown of glucosylceramide into glucose and ceramide. GBA1 is best known for its role in Gaucher disease when mutated - the most common lysosomal storage disorder. However, heterozygous GBA1 mutations are also the most significant genetic risk factor for [Parkinson's Disease[/diseases/parkinsons and [dementia with Lewy bodies[/diseases/lewy-body-dementia.
GBA1 mutations increase Parkinson's risk 5-20 fold depending on mutation severity, making genetic screening important for at-risk individuals.
Glucocerebrosidase is a 497-amino acid glycoprotein that folds in the endoplasmic reticulum and is trafficked to lysosomes via the mannose-6-phosphate pathway.
GBA1 mutations cause reduced enzyme activity, impaired glucosylceramide hydrolysis, and autophagy impairment. This lysosomal stress damages [neurons[/entities/neurons which rely heavily on autophagy for protein homeostasis.
A critical bidirectional relationship exists - GBA1 mutations increase [alpha-synuclein[/mechanisms/alpha-synuclein aggregation, and alpha-synuclein inhibits GBA, creating a vicious cycle. This GBA1-alpha-syn cycle explains why GBA1 carriers develop synucleinopathies.
GBA1 mutations activate [microglia[/entities/microglia and [astrocytes[/entities/astrocytes, contributing to neuroinflammation that accelerates neuronal dysfunction.
GBA1 deficiency impairs mitochondrial complex I activity and increases oxidative stress, mechanisms shared with idiopathic Parkinson's Disease.
| Mutation | Severity | Effect |
|---|---|---|
| N370S | Mild | High activity, common in Ashkenazi Jewish |
| L444P | Severe | Low activity, neuronopathic Gaucher |
| 84GG | Severe | Null allele |
| IVS2+1 | Severe | Splicing defect |
Ambroxol and GZ/SAR402671 are in clinical trials to stabilize mutant GBA1 and enhance lysosomal trafficking.
AAV-vector delivery of functional GBA1 and CRISPR-based gene correction are under development.
The study of Expanded Gba1 Page has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Page updated: 2026-03-01
GBA1 mutations represent significant risk factors for Parkinson's disease, and understanding the relationship between glucocerebrosidase and synuclein pathology is crucial for developing disease-modifying therapies. Research efforts are focused on enzyme enhancement therapies, gene therapy approaches, and small molecule chaperones that can restore GBA1 function.
Genetic testing for GBA1 mutations is recommended for patients with Parkinson's disease, especially those with a family history of the disease or early onset. Carriers of GBA1 mutations should be monitored for signs of cognitive decline and may benefit from early intervention strategies.
Glucocerebrosidase (GCase) is a lysosomal hydrolase encoded by the GBA1 gene. The enzyme catalyzes the hydrolysis of glucosylceramide (GlcCer) to glucose and ceramide within lysosomes. This reaction is essential for the degradation and recycling of glycosphingolipids, particularly in cells of the monocyte-macrophage system where glucosylceramide accumulation occurs in Gaucher disease.
GCase belongs to the glycoside hydrolase family and requires:
GCase hydrolyzes glucosylceramide and glucosylsphingosine (lyso-Gb1). The latter is a deacylated form that serves as a sensitive biomarker for GCase activity.
GBA1 mutations lead to reduced GCase activity, causing:
GCase and alpha-synuclein have a bidirectional relationship:
GBA1 mutations are associated with increased microglial activation and neuroinflammation in Parkinson's disease brains.
Small molecules that stabilize mutant GCase and enhance lysosomal trafficking:
AAV-vector delivery of wild-type GBA1 to restore enzymatic activity in the brain.
Inhibitors of glucosylceramide synthase to reduce substrate accumulation.